{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:15:37Z","timestamp":1780575337369,"version":"3.54.1"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["20S21900900"],"award-info":[{"award-number":["20S21900900"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["20S21901500"],"award-info":[{"award-number":["20S21901500"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010876","name":"Shanghai University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["2019YJ 06-01"],"award-info":[{"award-number":["2019YJ 06-01"]}],"id":[{"id":"10.13039\/501100010876","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014175","name":"Shanghai Municipal Commission of Health and Family Planning","doi-asserted-by":"publisher","award":["2020XGKY07"],"award-info":[{"award-number":["2020XGKY07"]}],"id":[{"id":"10.13039\/501100014175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bcp.2021.114724","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T02:48:33Z","timestamp":1628390913000},"page":"114724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2)"],"prefix":"10.1016","volume":"192","author":[{"given":"Yusen","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengge","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2021.114724_b0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.bcp.2021.114724_b0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0065-3527(06)66005-3","article-title":"The molecular biology of coronaviruses","volume":"66","author":"Masters","year":"2006","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.bcp.2021.114724_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114724_b0020","doi-asserted-by":"crossref","first-page":"e00473","DOI":"10.1128\/mBio.00473-12","article-title":"Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans","volume":"3","author":"van Boheemen","year":"2012","journal-title":"mBio"},{"issue":"4","key":"10.1016\/j.bcp.2021.114724_b0025","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bcp.2021.114724_b0030","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.virusres.2015.02.025","article-title":"The structure and functions of coronavirus genomic 3' and 5' ends","volume":"206","author":"Yang","year":"2015","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jsb.2010.11.021","article-title":"A structural analysis of M protein in coronavirus assembly and morphology","volume":"174","author":"Neuman","year":"2011","journal-title":"J. Struct. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114724_b0040","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3390\/v4030363","article-title":"The coronavirus E protein: assembly and beyond","volume":"4","author":"Ruch","year":"2012","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11373-005-9035-9","article-title":"Modular organization of SARS coronavirus nucleocapsid protein","volume":"13","author":"Chang","year":"2006","journal-title":"J. Biomed. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2021.114724_b0050","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses \u2014 drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"4","key":"10.1016\/j.bcp.2021.114724_b0055","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3390\/v4040557","article-title":"Ready, set, fuse! the coronavirus spike protein and acquisition of fusion competence","volume":"4","author":"Healdsargent","year":"2012","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.bcp.2021.114724_b0060","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/JVI.02232-10","article-title":"Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response","volume":"85","author":"Glowacka","year":"2011","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114724_b0065","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/JVI.02062-10","article-title":"A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry","volume":"85","author":"Shulla","year":"2011","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0070","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.bbrc.2007.05.092","article-title":"Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity","volume":"359","author":"Du","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"17","key":"10.1016\/j.bcp.2021.114724_b0075","doi-asserted-by":"crossref","first-page":"8887","DOI":"10.1128\/JVI.00415-08","article-title":"Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide","volume":"82","author":"Bosch","year":"2008","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114724_b0080","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2013a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114724_b0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"6377","key":"10.1016\/j.bcp.2021.114724_b0090","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/357420a0","article-title":"Human aminopeptidase N is a receptor for human coronavirus 229E","volume":"357","author":"Yeager","year":"1992","journal-title":"Nature"},{"issue":"7461","key":"10.1016\/j.bcp.2021.114724_b0095","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature12328","article-title":"Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26","volume":"500","author":"Lu","year":"2013","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.bcp.2021.114724_b0100","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1073\/pnas.1809667116","article-title":"Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A","volume":"116","author":"Hulswit","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"12","key":"10.1016\/j.bcp.2021.114724_b0105","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1073\/pnas.85.12.4526","article-title":"Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses","volume":"85","author":"Vlasak","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6965","key":"10.1016\/j.bcp.2021.114724_b0110","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.bcp.2021.114724_b0115","doi-asserted-by":"crossref","first-page":"7988","DOI":"10.1073\/pnas.0409465102","article-title":"Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry","volume":"102","author":"Hofmann","year":"2005","journal-title":"Proc. Natl. Acad.Sci. U.S.A."},{"issue":"7798","key":"10.1016\/j.bcp.2021.114724_b0120","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.2162","article-title":"The emerging role of ACE2 in physiology and disease","volume":"212","author":"Hamming","year":"2007","journal-title":"J. Pathol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114724_b0130","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ. Res."},{"issue":"20","key":"10.1016\/j.bcp.2021.114724_b0135","doi-asserted-by":"crossref","first-page":"17132","DOI":"10.1074\/jbc.M006723200","article-title":"Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys","volume":"276","author":"Zhang","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"6485","key":"10.1016\/j.bcp.2021.114724_b0140","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"issue":"7807","key":"10.1016\/j.bcp.2021.114724_b0145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0150","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"issue":"6483","key":"10.1016\/j.bcp.2021.114724_b0155","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.bcp.2021.114724_b0160","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2021.114724_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153364","article-title":"Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2","volume":"85","author":"Yu","year":"2021","journal-title":"Phytomedicine"},{"issue":"7","key":"10.1016\/j.bcp.2021.114724_b0170","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1021\/acs.jpclett.0c03119","article-title":"Kobophenol A inhibits binding of host ACE2 receptor with spike RBD domain of SARS-CoV-2, a lead compound for blocking COVID-19","volume":"12","author":"Gangadevi","year":"2021","journal-title":"J. Phys. Chem. Lett."},{"key":"10.1016\/j.bcp.2021.114724_b0175","doi-asserted-by":"crossref","unstructured":"H. Ohashi, K. Watashi, W. Saso, K. Shionoya, S. Iwanami, T. Hirokawa, T. Shirai, S. Kanaya, Y. Ito, K.S. Kim, K. Nishioka, S. Ando, K. Ejima, Y. Koizumi, T. Tanaka, S. Aoki, K. Kuramochi, T. Suzuki, K. Maenaka, T. Matano, M. Muramatsu, M. Saijo, K. Aihara, S. Iwami, M. Takeda, J.A. McKeating, T. Wakita, Multidrug treatment with nelfinavir and cepharanthine against COVID-19, bioRxiv (2020) 2020.04.14.039925.","DOI":"10.1101\/2020.04.14.039925"},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0180","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/molecules26010057","article-title":"Blocking effect of demethylzeylasteral on the interaction between human ACE2 protein and SARS-CoV-2 RBD protein discovered using SPR technology","volume":"26","author":"Zhu","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2021.114724_b0185","doi-asserted-by":"crossref","unstructured":"C. Mycroft-West, D. Su, S. Elli, Y. Li, S. Guimond, G. Miller, J. Turnbull, E. Yates, M. Guerrini, D. Fernig, M. Lima, M. Skidmore, The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding, bioRxiv (2020) 2020.02.29.971093.","DOI":"10.1101\/2020.02.29.971093"},{"issue":"10","key":"10.1016\/j.bcp.2021.114724_b0190","doi-asserted-by":"crossref","first-page":"e02002","DOI":"10.1128\/JVI.02002-17","article-title":"Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the middle east respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape","volume":"92","author":"Wang","year":"2018","journal-title":"J. Virol."},{"issue":"7238","key":"10.1016\/j.bcp.2021.114724_b0195","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nature07930","article-title":"Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals","volume":"458","author":"Scheid","year":"2009","journal-title":"Nature"},{"issue":"6279","key":"10.1016\/j.bcp.2021.114724_b0200","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0205","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg. Microbes Infect."},{"issue":"6496","key":"10.1016\/j.bcp.2021.114724_b0210","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0215","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2021.114724_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104820","article-title":"Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2","volume":"179","author":"Tai","year":"2020","journal-title":"Antiv. Res."},{"issue":"7819","key":"10.1016\/j.bcp.2021.114724_b0225","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"issue":"6428","key":"10.1016\/j.bcp.2021.114724_b0230","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bcp.2021.114724_b0235","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1110\/ps.34602","article-title":"Single-domain antibody fragments with high conformational stability","volume":"11","author":"Dumoulin","year":"2002","journal-title":"Protein Sci."},{"issue":"3","key":"10.1016\/j.bcp.2021.114724_b0240","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1074\/jbc.M111.242818","article-title":"Dual beneficial effect of interloop disulfide bond for single domain antibody fragments","volume":"287","author":"Govaert","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0245","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0167-4838(99)00030-8","article-title":"Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies","volume":"1431","author":"van der Linden","year":"1999","journal-title":"Biochim. Biophys. Acta, Mol. Cell. Biol. Lipids"},{"issue":"5","key":"10.1016\/j.bcp.2021.114724_b0250","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cell.2020.04.031","article-title":"Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies","volume":"181","author":"Wrapp","year":"2020","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bcp.2021.114724_b0255","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3390\/jcm9051473","article-title":"Highly conserved homotrimer cavity formed by the SARS-CoV-2 spike glycoprotein: a novel binding site","volume":"9","author":"Kalathiya","year":"2020","journal-title":"J Clin Med"},{"issue":"9413","key":"10.1016\/j.bcp.2021.114724_b0260","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(04)15788-7","article-title":"Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors","volume":"363","author":"Liu","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bcp.2021.114724_b0265","doi-asserted-by":"crossref","first-page":"eaav4580","DOI":"10.1126\/sciadv.aav4580","article-title":"A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike","volume":"5","author":"Xia","year":"2019","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.bcp.2021.114724_b0270","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.bcp.2021.114724_b0275","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/infdis\/jiy152","article-title":"Fusion inhibitory lipopeptides engineered for prophylaxis of nipah virus in primates","volume":"218","author":"Mathieu","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"11","key":"10.1016\/j.bcp.2021.114724_b0280","first-page":"e00288","article-title":"A lipopeptide HIV-1\/2 fusion inhibitor with highly potent in vitro ex vivo, and in vivo antiviral activity","volume":"91","author":"Chong","year":"2017","journal-title":"J. Virol.s"},{"issue":"14","key":"10.1016\/j.bcp.2021.114724_b0285","doi-asserted-by":"crossref","first-page":"e00635","DOI":"10.1128\/JVI.00635-20","article-title":"Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity","volume":"94","author":"Zhu","year":"2020","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114724_b0290","doi-asserted-by":"crossref","first-page":"2000224","DOI":"10.1002\/adtp.202000224","article-title":"Drug repurposing of itraconazole and estradiol benzoate against COVID-19 by blocking SARS-CoV-2 spike protein-mediated membrane fusion","volume":"4","author":"Yang","year":"2021","journal-title":"Adv. Therapeut."},{"issue":"20","key":"10.1016\/j.bcp.2021.114724_b0295","doi-asserted-by":"crossref","first-page":"11334","DOI":"10.1128\/JVI.78.20.11334-11339.2004","article-title":"Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells","volume":"78","author":"Yi","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2021.114724_b0300","doi-asserted-by":"crossref","unstructured":"Y. Zhao, Z. Zhao, Y. Wang, Y. Zhou, Y. Ma, W. Zuo, Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov, bioRxiv (2020) 2020.01.26.919985.","DOI":"10.1101\/2020.01.26.919985"},{"issue":"2","key":"10.1016\/j.bcp.2021.114724_b0305","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0310","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.me.40.020189.002243","article-title":"Pulmonary surfactant","volume":"40","author":"Dobbs","year":"1989","journal-title":"Annu. Rev. Med."},{"issue":"6","key":"10.1016\/j.bcp.2021.114724_b0315","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1161\/01.HYP.0000146120.29648.36","article-title":"Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor","volume":"44","author":"Huentelman","year":"2004","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.bcp.2021.114724_b0320","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1007\/s00216-021-03233-7","article-title":"Screening and evaluation of anti-SARS-CoV-2 components from Ephedra sinica by ACE2\/CMC-HPLC-IT-TOF-MS approach","volume":"413","author":"Lv","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0325","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41392-021-00584-6","article-title":"Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2","volume":"6","author":"Huang","year":"2021","journal-title":"Sig. Trans. Targeted Ther."},{"issue":"9","key":"10.1016\/j.bcp.2021.114724_b0330","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.scib.2020.12.005","article-title":"Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2","volume":"66","author":"Gu","year":"2021","journal-title":"Sci. Bull. (Beijing)"},{"key":"10.1016\/j.bcp.2021.114724_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2019.104350","article-title":"ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway","volume":"113","author":"Ye","year":"2020","journal-title":"Exp. Mol. Pathol."},{"issue":"11","key":"10.1016\/j.bcp.2021.114724_b0340","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1681\/ASN.2006050423","article-title":"Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes","volume":"17","author":"Ye","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0345","doi-asserted-by":"crossref","first-page":"20250","DOI":"10.1038\/s41598-020-76915-4","article-title":"Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study","volume":"10","author":"Lim","year":"2020","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.bcp.2021.114724_b0350","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"issue":"4","key":"10.1016\/j.bcp.2021.114724_b0355","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.bcp.2021.114724_b0360","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects","volume":"52","author":"Haschke","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0365","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit. Care"},{"issue":"5","key":"10.1016\/j.bcp.2021.114724_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"11","key":"10.1016\/j.bcp.2021.114724_b0375","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today's diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0380","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J."},{"issue":"3","key":"10.1016\/j.bcp.2021.114724_b0385","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.bcp.2021.114724_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109783","article-title":"Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection","volume":"142","author":"Klimke","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"8","key":"10.1016\/j.bcp.2021.114724_b0395","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","article-title":"Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion","volume":"14","author":"Mauthe","year":"2018","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0400","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","article-title":"Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate","volume":"75","author":"McChesney","year":"1983","journal-title":"Am. J. Med."},{"issue":"15","key":"10.1016\/j.bcp.2021.114724_b0405","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bcp.2021.114724_b0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/128_2013_466","article-title":"Sialic acid receptors of viruses","volume":"367","author":"Matrosovich","year":"2013","journal-title":"Top. Curr. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2021.114724_b0415","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41594-019-0233-y","article-title":"Structural basis for human coronavirus attachment to sialic acid receptors","volume":"26","author":"Tortorici","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114724_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105960","article-title":"Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection","volume":"55","author":"Fantini","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.bcp.2021.114724_b0425","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.virusres.2014.11.021","article-title":"Host cell proteases: critical determinants of coronavirus tropism and pathogenesis","volume":"202","author":"Millet","year":"2015","journal-title":"Virus Res."},{"issue":"3","key":"10.1016\/j.bcp.2021.114724_b0430","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.antiviral.2013.09.028","article-title":"Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research","volume":"100","author":"Simmons","year":"2013","journal-title":"Antiviral Res."},{"issue":"6","key":"10.1016\/j.bcp.2021.114724_b0435","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3390\/v4061011","article-title":"Mechanisms of coronavirus cell entry mediated by the viral spike protein","volume":"4","author":"Belouzard","year":"2012","journal-title":"Viruses"},{"issue":"14","key":"10.1016\/j.bcp.2021.114724_b0440","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1128\/JVI.00998-13","article-title":"Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms","volume":"87","author":"Adedeji","year":"2013","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114724_b0445","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1124\/mol.110.064261","article-title":"A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells","volume":"78","author":"Shah","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114724_b0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biochi.2017.07.016","article-title":"TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections","volume":"142","author":"Shen","year":"2017","journal-title":"Biochimie"},{"issue":"2","key":"10.1016\/j.bcp.2021.114724_b0455","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bcp.2021.114724_b0460","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/2159-8290.CD-13-1010","article-title":"The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis","volume":"4","author":"Lucas","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2021.114724_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104853","article-title":"Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2","volume":"157","author":"Habtemariam","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2021.114724_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104837","article-title":"Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection","volume":"157","author":"Maggio","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.bcp.2021.114724_b0475","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1083\/jcb.200108123","article-title":"Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis","volume":"156","author":"Conner","year":"2002","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2021.114724_b0480","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.antiviral.2018.05.001","article-title":"Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment","volume":"155","author":"Pu","year":"2018","journal-title":"Antiv. Res."},{"issue":"10223","key":"10.1016\/j.bcp.2021.114724_b0485","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bcp.2021.114724_b0490","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/jcp.30032","article-title":"Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: a systematic review of in vitro and in vivo studies","volume":"236","author":"Seyedpour","year":"2021","journal-title":"J. Cell. Physiol."},{"issue":"8","key":"10.1016\/j.bcp.2021.114724_b0495","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.drudis.2020.06.017","article-title":"Discovering small-molecule therapeutics against SARS-CoV-2","volume":"25","author":"Tiwari","year":"2020","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0500","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12967-020-02344-6","article-title":"Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant","volume":"18","author":"Pachetti","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2021.114724_b0505","doi-asserted-by":"crossref","unstructured":"A.T. Widge, N.G. Rouphael, L.A. Jackson, E.J. Anderson, P.C. Roberts, M. Makhene, J.D. Chappell, M.R. Denison, L.J. Stevens, A.J. Pruijssers, A.B. McDermott, B. Flach, B.C. Lin, N.A. Doria-Rose, S. O'Dell, S.D. Schmidt, K.M. Neuzil, H. Bennett, B. Leav, M. Makowski, J. Albert, K. Cross, V.V. Edara, K. Floyd, M.S. Suthar, W. Buchanan, C.J. Luke, J.E. Ledgerwood, J.R. Mascola, B.S. Graham, J.H. Beigel, R.N.A.S.G. m, Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination, N Engl J Med 384(1) (2021) 80-82.","DOI":"10.1056\/NEJMc2032195"},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0510","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"6","key":"10.1016\/j.bcp.2021.114724_b0515","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet. Infect. Dis"},{"issue":"6523","key":"10.1016\/j.bcp.2021.114724_b0520","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.abe8499","article-title":"SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo","volume":"370","author":"Hou","year":"2020","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.bcp.2021.114724_b0525","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/S2666-5247(21)00068-9","article-title":"SARS-CoV-2 spike E484K mutation reduces antibody neutralisation","volume":"2","author":"Jangra","year":"2021","journal-title":"Lancet Microbe"},{"issue":"5","key":"10.1016\/j.bcp.2021.114724_b0530","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.cell.2021.01.037","article-title":"Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity","volume":"184","author":"Thomson","year":"2021","journal-title":"Cell"},{"issue":"6534","key":"10.1016\/j.bcp.2021.114724_b0535","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1126\/science.abg7404","article-title":"Immunity to SARS-CoV-2 variants of concern","volume":"371","author":"Altmann","year":"2021","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bcp.2021.114724_b0540","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"7154","key":"10.1016\/j.bcp.2021.114724_b0545","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/448645a","article-title":"New uses for old drugs","volume":"448","author":"Chong","year":"2007","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41422-020-00447-9","article-title":"SARS-CoV-2-induced lung pathology: AHR as a candidate therapeutic target","volume":"31","author":"Giovannoni","year":"2021","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.bcp.2021.114724_b0555","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41590-020-00835-8","article-title":"Establishment of an African green monkey model for COVID-19 and protection against re-infection","volume":"22","author":"Woolsey","year":"2021","journal-title":"Nat. Immunol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221003403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221003403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:10:35Z","timestamp":1762096235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221003403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":111,"alternative-id":["S0006295221003403"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114724","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2)","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114724"}}